Measurement of TSH receptor blocking immunoglobulins using <sup>3</sup>H‐adenine incorporation into FRTL‐5 and JPO9 cells: use in a child with neonatal hypothyroidism

Vp, Michelangeli; Cw, Poon; Ee, Arnus; Ag, Frauman; Connelly, John F.; Colman, Peter G

doi:10.1111/j.1365-2265.1995.tb02596.x

Cited by 11 publications

(8 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2a), this serum dilution seems to be optimal for the determination of TSAB in hypotonic Krebs Ringer Buffer. These findings are in agreement with the serum buffer dilution of 1/5–1/10 in hypotonic Hanks buffer used by Michelangeli et al (1994, 1995). Considering a normal IgG concentration of 10–18 g/l and the used serum/buffer dilution of 1/10 our TSHR AB bioassay was performed with an IgG concentration of 1–1.8 g/l.…”

Section: Discussionsupporting

confidence: 91%

Detection of thyroid stimulating (TSAB)‐ and thyrotropin stimulation blocking (TSBAB) antibodies with CHO cell lines expressing different TSH‐receptor numbers

Wallaschofski¹,

Paschke²

1999

Clinical Endocrinology

View full text Add to dashboard Cite

Improvement of CHO bioassay conditions for the determination of TSH receptor antibodies leads to increased bioassay sensitivity which is most pronounced for the detection of TSBAB. Whether this increased sensitivity for the determination of TSBAB is of prognostic significance for detecting possible sequential changes in the individual TSHR AB profile of patients with Graves' disease, remains to be determined by further follow up studies.

show abstract

Section: Discussionsupporting

confidence: 91%

Detection of thyroid stimulating (TSAB)‐ and thyrotropin stimulation blocking (TSBAB) antibodies with CHO cell lines expressing different TSH‐receptor numbers

Wallaschofski¹,

Paschke²

1999

Clinical Endocrinology

View full text Add to dashboard Cite

show abstract

“…DELFIA free thyroxine (FT4) and DELFIA hTSH kits were purchased from Kabi Pharmacia (Wallac Oy, Turku, Finland). The interassay coefficients of variation were 11% (6-8 pmol/L), 7% (16)(17)(18)(19) pmol/L), and 8% (43-53 pmol/L) for the fT4 assay, and 6% (0.77-1.03 mU/L), 4% (4.3-5.7 mU/L), and 3% (22)(23)(24)(25)(26)(27)(28)(29)(30) (20,21). For as¬ says, the cells were subcultured onto 12-well plates and grown to confluence.…”

Section: Methodsmentioning

confidence: 99%

“…We have recently reported new assays for the measurement of TSAb and TBAb using a method involving incorporation of [3H]adenine into FRTL-5 or JP09 cells and measuring the intracellular production of cAMP directly (17)(18)(19). These assays can be used to measure the specific activities of antibodies in serum.…”

mentioning

confidence: 98%

Specific Effects of Radioiodine Treatment on TSAb and TBAb Levels in Patients with Graves' Disease

Michelangeli

Poon²,

Topliss³

et al. 1995

Thyroid

View full text Add to dashboard Cite

Radioactive iodine (RAI)-induced changes in the levels of antibodies to the thyroid-stimulating hormone (TSH) re¬ ceptor (TRAb) in patients undergoing treatment for autoimmune thyroid disease have been well documented. Previous studies have reported effects on the overall level of the antibodies present, TSH-binding inhibitory im¬ munoglobulins (TBII), without detailed studies of specific effects on the levels of thyroid-stimulating (TSAb) or thy¬ roid-blocking antibodies (TBAb). More detailed studies have been reported only in individual cases. In this study, the values of TSAb, TBAb, and TBII were measured longitudinally in 33 patients (27 females and 6 males) who re¬ ceived RAI. The bioassays for TSAb and TBAb were performed in JP09 cells. Following RAI, there were signifi¬ cant and immediate effects on the values of TBII in 70% of patients. TBII levels fell in 7 patients (20%) (Group 1), rose in 16 patients (48%) (Group 2) or remained unchanged but elevated in 10 patients (32%) (Group 3). In the Group 1 patients, only TSAb were detectable and none of these patients became hypothyroid after treatment. In the 16 patients in Group 2, increases in TBII were attributable to specific increases in TSAb in 7 (44%), in TBAb in 3 (19%), and in both TSAb and TBAb in 3 (19%). There were 3 patients (19%) in this group in whom there was no detectable TSAb or TBAb activity despite the increase in TBII. Six patients from this group became hypothy¬ roid within 6 months of RAI treatment. In the 10 patients in Group 3, 5 patients (50%) were positive for TBAb only, 2 (20%) were TSAb-only positive, and 3 (30%) were both TSAb-and TBAb-positive. Five patients (50%) in this group became hypothyroid and all had TBAb present in their circulation. Our results show that there are di¬ verse changes in TBII, TSAb, and TBAb following RAI. Hypothyroidism occurred in 33% of the patients treated with RAI therapy and TBAb were present in 75% of these hypothyroid patients. When TBAb were present in the absence of TSAb, hypothyroidism occurred in 6 of 8 versus 3 of 14 where TSAb were present alone (p < 0.05). The development of hypothyroidism within 6 months of RAI treatment was not related to continuation or dosage of an¬ tithyroid drugs and was transient in 50% of patients. We conclude that early hypothyroidism following RAI ther¬ apy is associated with increased TBAb in some patients and that recognition of this clinical situation should avoid unnecessary life-long thyroxine replacement.

show abstract

“…Total T 3 and T 4 concentrations were determined using a corresponding EIA kit from Diagnostic Systems Laboratories (Webster, TX, USA). The activity of TSH receptor (TSHR)-stimulating antibody (TSAb) was measured by cell bioassay as described by Costagliola et al (1992) and Michelangeli et al (1995), and expressed as a percent increase in TSHRinduced cAMP production compared to the normal pool serum. Antithyroid peroxidase antibodies (anti-TPO Ab) were detected using a radioimmunoassay DYNO test antiTPOAb (Brahms Diagnostica GmBH, Berlin, Germany), with a cut-off for positivity of 100 U/ml (Feldt-Rasmussen et al 1991).…”

Section: Subjects and Gd Diagnosismentioning

confidence: 99%

The −112G > A polymorphism of the secretoglobin 3A2 (SCGB3A2) gene encoding uteroglobin-related protein 1 (UGRP1) increases risk for the development of Graves’ disease in subsets of patients with elevated levels of immunoglobulin E

et al. 2010

View full text Add to dashboard Cite

The human secretoglobin 3A2 (SCGB3A2) gene encoding secretory uteroglobin-related protein 1 (UGRP1) resides on the chromosome region 5q31-33 that harbors a susceptibility locus to several autoimmune and inflammatory diseases, including asthma and Graves' disease (GD). Recently, association between the marker rs1368408 (-112G >A), located in the promoter region of the SCGB3A2 gene, and susceptibility to GD was found in Chinese and UK Caucasians. The study aim was to evaluate whether this polymorphism confers GD susceptibility in a large population cohort comprising 1,474 Russian GD patients and 1,619 controls. The marker rs1368408 was studied using a TaqMan allele discrimination assay. Serum levels of UGRP1 and immunoglobulin E (IgE) were assessed using enzyme-linked immunosorbent assay (ELISA) analyses. Association between the allele A of SCGB3A2 and a higher risk of GD (odds ratio [OR] = 1.33, P = 2.9 × 10(-5)) was shown. Both affected and non-affected carriers of the higher risk genotype A/A had significantly decreased levels of serum UGRP1 compared to the subjects homozygous for G/G (93 ± 37 pg/ml vs. 132 ± 45 pg/ml, P = 0.0011 for GD patients; 77 ± 28 pg/ml vs. 119 ± 33 pg/ml, P = 0.0019 for controls). Serum IgE levels were significantly higher in non-affected subjects homozygous for A/A compared to control individuals homozygous for G/G (153 ± 46 IU/ml vs. 122 ± 40 IU/ml, P = 0.0095). Our data suggest that the carriage of the SCGB3A2 -112A/A variant increases the risk for GD in subsets of patients with elevated levels of IgE, a hallmark of allergic asthma. Therefore, the SCGB3A2 -112G >A polymorphism may be considered as a likely marker linking susceptibility to allergy/asthma and GD on chromosome 5q31-33.

show abstract

Measurement of TSH receptor blocking immunoglobulins using ³H‐adenine incorporation into FRTL‐5 and JPO9 cells: use in a child with neonatal hypothyroidism

Abstract: This case of neonatal hypothyroidism associated with the passage of thyroid blocking antibodies demonstrates the utility of this new assay in the differential diagnosis of neonatal hypothyroidism.

Cited by 11 publications

References 21 publications

Detection of thyroid stimulating (TSAB)‐ and thyrotropin stimulation blocking (TSBAB) antibodies with CHO cell lines expressing different TSH‐receptor numbers

Detection of thyroid stimulating (TSAB)‐ and thyrotropin stimulation blocking (TSBAB) antibodies with CHO cell lines expressing different TSH‐receptor numbers

Specific Effects of Radioiodine Treatment on TSAb and TBAb Levels in Patients with Graves' Disease

The −112G > A polymorphism of the secretoglobin 3A2 (SCGB3A2) gene encoding uteroglobin-related protein 1 (UGRP1) increases risk for the development of Graves’ disease in subsets of patients with elevated levels of immunoglobulin E

Contact Info

Product

Resources

About

Measurement of TSH receptor blocking immunoglobulins using 3H‐adenine incorporation into FRTL‐5 and JPO9 cells: use in a child with neonatal hypothyroidism

Abstract: This case of neonatal hypothyroidism associated with the passage of thyroid blocking antibodies demonstrates the utility of this new assay in the differential diagnosis of neonatal hypothyroidism.

Cited by 11 publications

References 21 publications

Detection of thyroid stimulating (TSAB)‐ and thyrotropin stimulation blocking (TSBAB) antibodies with CHO cell lines expressing different TSH‐receptor numbers

Detection of thyroid stimulating (TSAB)‐ and thyrotropin stimulation blocking (TSBAB) antibodies with CHO cell lines expressing different TSH‐receptor numbers

Specific Effects of Radioiodine Treatment on TSAb and TBAb Levels in Patients with Graves' Disease

The −112G > A polymorphism of the secretoglobin 3A2 (SCGB3A2) gene encoding uteroglobin-related protein 1 (UGRP1) increases risk for the development of Graves’ disease in subsets of patients with elevated levels of immunoglobulin E

Contact Info

Product

Resources

About

Measurement of TSH receptor blocking immunoglobulins using ³H‐adenine incorporation into FRTL‐5 and JPO9 cells: use in a child with neonatal hypothyroidism